Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

SELDI-TOF MS Combined with Magnetic Beads for Detecting Serum Protein Biomarkers and Establishment of a Boosting Decision Tree Model for Diagnosis of Pancreatic Cancer

  • Qian, Jing-Yi (Medical Services Section, Taizhou Municipal Hospital) ;
  • Mou, Si-Hua (Department of Clinical Laboratory, Taizhou Municipal Hospital) ;
  • Liu, Chi-Bo (Department of Clinical Laboratory, Taizhou Municipal Hospital)
  • Published : 2012.05.30
Download PDF
⟨ Previous Next ⟩

Abstract

Aim: New technologies for the early detection of pancreatic cancer (PC) are urgently needed. The aim of the present study was to screen for the potential protein biomarkers in serum using proteomic fingerprint technology. Methods: Magnetic beads combined with surface-enhanced laser desorption/ionization (SELDI) TOF MS were used to profile and compare the protein spectra of serum samples from 85 patients with pancreatic cancer, 50 patients with acute-on-chronic pancreatitis and 98 healthy blood donors. Proteomic patterns associated with pancreatic cancer were identified with Biomarker Patterns Software. Results: A total of 37 differential m/z peaks were identified that were related to PC (P < 0.01). A tree model of biomarkers was constructed with the software based on the three biomarkers (7762 Da, 8560 Da, 11654 Da), this showing excellent separation between pancreatic cancer and non-cancer., with a sensitivity of 93.3% and a specificity of 95.6%. Blind test data showed a sensitivity of 88% and a specificity of 91.4%. Conclusions: The results suggested that serum biomarkers for pancreatic cancer can be detected using SELDI-TOF-MS combined with magnetic beads. Application of combined biomarkers may provide a powerful and reliable diagnostic method for pancreatic cancer with a high sensitivity and specificity.

Keywords

References

  1. Adam BL, Qu Y, Davis JW, et al (2002). Serum protein fingerprinting coupled with a pattern-matching algorithm distinguishes prostate cancer from benign prostate hyperplasia and healthy men. Cancer Res, 62, 3609-14.
  2. DiMagno EP, Reber HA, Tempero MA (1999). Epidemiology, diagnosis, and treatment of pancreatic ductal adenocarcinoma. Gastroenterology, 117, 1463-84. https://doi.org/10.1016/S0016-5085(99)70297-0
  3. Ebert MP, Meuer J, Wiemer JC, et al (2004). Identification of gastric cancer patients by serum protein profiling. J Proteome Res, 3, 1261-6. https://doi.org/10.1021/pr049865s
  4. Guo R, Pan C, Shen J, et al (2011). New serum biomarkers for detection of esophageal carcinoma using Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. J Cancer Res Clin Oncol, 137, 513-9. https://doi.org/10.1007/s00432-010-0899-3
  5. Hortin GL (2006). The MALDI-TOF mass spectrometric view of the plasma proteome and peptidome. Clin Chem, 52, 1223-37. https://doi.org/10.1373/clinchem.2006.069252
  6. Liu C, Pan C, Shen J, et al (2011). MALDI-TOF MS combined with magnetic beads for detecting serum protein biomarkers and establishment of boosting decision tree model for diagnosis of colorectal cancer. Int J Med Sci, 8, 39-47. https://doi.org/10.7150/ijms.8.39
  7. Liu C, Wang H, Pan C, et al (2010). Serum protein fingerprint of patients with gastric cancer by SELDI technology. African J Biotechnol, 9, 2298-304.
  8. Kim JE, Lee KT, Lee JK, et al (2004). Clinical usefulness of Carbohydrate antigen 199 as a screening test for pancreatic cancer in an asymptomatic population. J Gastroenterol Hepatol, 19, 182-6. https://doi.org/10.1111/j.1440-1746.2004.03219.x
  9. Kim EJ, Simeone DM, (2011). Advances in pancreatic cancer. Curr Opin Gastroenterol, 27, 460-6. https://doi.org/10.1097/MOG.0b013e328349e31f
  10. Liang Y, Fang M, Li J, et al (2006). Serum proteomic patterns for gastric lesions as revealed by SELDI mass spectrometry. Exp Mol Pathol, 81, 176-80. https://doi.org/10.1016/j.yexmp.2006.04.008
  11. Li D, Xie K, Wolff R, et al (2004). Pancreatic cancer. Lancet, 363, 1049-57. https://doi.org/10.1016/S0140-6736(04)15841-8
  12. Liotta LA, Ferrari M, Petricoin E (2003). Clinical proteomics: written in blood. Nature, 425, 905. https://doi.org/10.1038/425905a
  13. Liu CB, Liang Y, Pan CQ, et al (2009). Proteome study of differential protein expression in HBV-related primary hepatic carcinoma. Chem J Chinese Universities, 30, 1763-6.
  14. Liu C, Shen J, Pan C, et al (2010). MALDI-TOF MS combined with magnetic beads for detecting serum protein biomarkers and establishment of boosting decision tree model for diagnosis of hepatocellular carcinoma. Am J Clin Pathol, 134, 235-41 https://doi.org/10.1309/AJCPA6C6NOGFLYIR
  15. Schwegler EE, Cazares L, Steel LF, et al (2005). SELDI-TOF MS profiling of serum for detection of the progression of chronic hepatitis C to hepatocellular carcinoma. Hepatology, 41, 634-42. https://doi.org/10.1002/hep.20577
  16. Semmes OJ, Feng Z, Adam BL, et al (2005). Evaluation of serum protein profiling by surface-enhanced laser desorption/ ionization time-of-flight mass spectrometry for the detection of prostate cancer: I. Assessment of platform reproducibility. Clin Chem, 51, 102-12.
  17. Singh S, Tang SJ, Sreenarasimhaiah J, et al (2011). The clinical utility and limitations of serum carbohydrate antigen (CA19-9) as a diagnostic tool for pancreatic cancer and cholangiocarcinoma. Dig Dis Sci, 56, 2491-6. https://doi.org/10.1007/s10620-011-1709-8
  18. Wagner M, Naik DN, Pothen A, et al (2004). Computational protein biomarker prediction: a case study for prostate cancer. BMC Bioinformatics, 5, 26. https://doi.org/10.1186/1471-2105-5-26
  19. Ward DG, Cheng Y, N'Kontchou G, et al (2006). Preclinical and post-treatment changes in the HCC-associated serum proteome. Br J Cancer, 95, 1379-83. https://doi.org/10.1038/sj.bjc.6603429
  20. Ward DG, Suggett N, Cheng Y, et al (2006). Identification of serum biomarkers for colon cancer by proteomic analysis. Br J Cancer, 94, 1898-905. https://doi.org/10.1038/sj.bjc.6603188

Cited by

  1. Biomarkers Screening Between Preoperative and Postoperative Patients in Pancreatic Cancer vol.14, pp.7, 2013, https://doi.org/10.7314/APJCP.2013.14.7.4161
  2. Identification of patients with nasopharyngeal carcinoma by serum protein profiling using surface-enhanced laser desorption/ionization time-of-flight mass spectrometry vol.19, pp.4, 2014, https://doi.org/10.1007/s10147-013-0621-y
  3. Alterations in the serum proteome profile during the development of ovarian cancer vol.45, pp.6, 2014, https://doi.org/10.3892/ijo.2014.2675
  4. Serum protein profiles of patients with lung cancer of different histological types vol.12, pp.1, 2016, https://doi.org/10.1111/ajco.12441
  5. Pancreatic cancer: diagnosis and treatments vol.36, pp.3, 2015, https://doi.org/10.1007/s13277-015-3223-7